Luciano J. Costa, MD, PhD, shares results from a first-in-human trial of CC-93269, a bispecific antibody that targets B-cell maturation antigen and CD3 T cells, which was associated with a "manageable" safety profile and 43% overall response rate.
Luciano J. Costa, MD, PhD, shares results from a first-in-human trial of CC-93269, a bispecific antibody that targets B-cell maturation antigen and CD3 T cells, which was associated with a "manageable" safety profile and 43% overall response rate.
Connect with us:
CURRENT ISSUE
June 2025
